RxDoctor Payments DataLook up a doctor →

Brian le, MD

Clinical Cardiac Electrophysiology · Dallas, TXNPI 1235138306

Payments from drug & device makers

$114,663in general payments, 2019–2025

Across 498 payments — averaging $230.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$48K
  • Johnson & Johnson$29K
  • E.r. Squibb & Sons, L.L.C.$14K
  • Pfizer$9K
  • Abbott$8K
  • Sanofi-aventis U.S. LLC$2K
  • plus $5K from 25 others

What the payments were for

  • Consulting fees$29,36029%
  • Speaking & faculty fees$46,81046%
  • Grants$4,0004%
  • Travel & lodging$6,8167%
  • Food & beverage$14,94515%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$114,663 in reported general payments places this provider in the 75th percentile of 233 clinical cardiac electrophysiology providers in Texas.

See all clinical cardiac electrophysiology providers in Texas

Medicare billing

Part B allowed, 2024
$603,937
Medicare patients
1,263
Services billed
6,734

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban461$554,931
XareltoRivaroxaban138$158,270
MultaqDronedarone Hcl20$33,448
Propafenone Hcl ErPropafenone Hcl152$17,809
EntrestoSacubitril/Valsartan20$17,388
Repatha SureclickEvolocumab20$12,338
SotalolSotalol Hcl452$9,620
Mexiletine Hcl75$7,111
Amiodarone Hcl367$5,466
Propafenone Hcl117$4,868
Flecainide Acetate115$4,463
Metoprolol Succinate173$2,878
Dabigatran EtexilateDabigatran Etexilate Mesylate11$2,330
ClopidogrelClopidogrel Bisulfate146$1,986
Carvedilol192$1,882

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$9,436$554,931461 claims
Johnson & JohnsonXarelto$28,769$158,270138 claims
Sanofi-aventis U.S. LLCMultaq$1,749$33,44820 claims
NovartisEntresto$221$17,38820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 233 clinical cardiac electrophysiology providers in Texas.

Other clinical cardiac electrophysiology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →